Sep 30 |
Nektar rises 11% as BTIG initiates buy rating on autoimmune disorders asset
|
Sep 25 |
Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024
|
Sep 11 |
Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?
|
Aug 13 |
What Makes Nektar (NKTR) a New Buy Stock
|
Aug 10 |
Nektar Therapeutics (NKTR) Q2 2024 Earnings Call Transcript
|
Aug 10 |
Nektar Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
Aug 9 |
Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top
|
Aug 8 |
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
|
Aug 8 |
Nektar Therapeutics Non-GAAP EPS of -$0.19, revenue of $23.49M
|
Aug 8 |
Nektar: Q2 Earnings Snapshot
|